Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data ‘demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing’ with both three and six milligram cohorts showing the ‘highest immune activation’, while the drug produced a 50% remission rate in doublet dose cohorts.
Chief Executive Officer Markku Jalkanen says: ‘This is a significant milestone...The emerging bexmarilimab data from the Phase 1 part of the study have been very encouraging, showing continued efficacy signals and long duration of responses. We believe that bexmarilimab has the potential to improve patient outcomes and improve quality of life for those suffering from MDS, addressing the longstanding unmet medical needs in conditions which have had no new effective treatments in decades.’
Current stock price: 270.50 pence, up 6.1% on Monday in London
12-month change: up 52%
Copyright 2023 Alliance News Ltd. All Rights Reserved.